Skip navigation

Life Science Leadership Series: Cancer Immunotherapies

08.30 – 18.30

Barry Cross Conference Centre, Babraham Research Campus, Cambridge CB22 3AT
12 February 2015
The Life Science Leadership Series are one day conferences focused on a specific therapeutic or technology area.  The first one of this year will be held on the 12 February 2015 and will focus on Immunotherapy in Cancer.  This day aims to deliver a first class programme, bringing people together from various areas of the sector to debate the issues faced in this therapeutic area.  The event will also provide the perfect environment for networking during the day.

*Registration closed*
This event has reached capacity and therefore registration is now closed.
Please email to be added to the waiting list.

Sponsored by: Supported by:


08.30 - Registration opens

09.15 - Welcome

Tony Jones, Business Development Director, One Nucleus 

09.25 - Introduction to today’s agenda
Alain Rachon, Business Developer Biotech Start-up, Merck Millipore
*To view the presentation, please click here.

09.35 - Chair's Scene Setting

Viia Valge-Archer, Principal Scientist, Oncology, MedImmune

09.45 - An Insider View to the Recent Merck-Pfizer Immuno-Oncology Alliance

Tamara Wells, Director Business Development Oncology, Merck Serono

10.15 - History and Drivers of the Current Focus on Immunotherapy 

Adrian Dawkes, PharmaVentures 

*To view the presentation, click here.

10.45 – 11.15 - Tea/Coffee Break and networking

11.15 – 12.45 - Plenary Session: Innovative Approaches to New Therapeutics

11.15 - Introduction from the Chair, Dr Neill Mackenzie, CBO, Biotecnol Ltd

11.20 - Targeting CD95-CD95L system in tumours  

Davidson Ateh, CEO, BioMoti 
*To view the presentation, click here.

11.40 - Kymab: A Leader in Therapeutic Antibody Discovery and Transformational Drugs in Immuno-oncology

Steve Arkinstall, Chief Scientific Officer, Kymab
*To receive the presentation, please contact

12.00 - ImmTACs, a new class of immune-oncology therapeutic

Stephen Megit, Director of Business Development, Immunocore
*To view the presentation, please click here.

12.20 - A new class of antibody derived T-cell engagers
Dr Neill Mackenzie, CBO, Biotecnol Ltd
*To view the presentation, please click here.

12.40 – 14.00 - Lunch and Networking

14.00 – 15.05 - Plenary Session: Engaging External Expertise

14.00 - Introduction from the Chair

14.05 - Setting a reliable contract with a CDO partner: Key criteria to consider
Florence L’Hospice, Innate Pharma 


14.25 - Working with PDX models for early proof of concept       

Rajendra Kumari, CSO, PRECOS, a Crowne Bioscience company

14.45 - A Check List for First in Man Approval 

Richard Turner, Principal Consultant, Clinical Network Services (UK) 

*To view the presentation, please click here.

15.05 - Chair’s closing remarks

15.05 – 15.45 - Tea/Coffee Break and Networking

15.45 – 17.10 - Plenary Session: Leveraging Partnerships and Investors to Enhance Development            

15.45 - Introduction from the Chair
Tony Jones, Business Development Director, One Nucleus 

15.50 - Managing a successful biodevelopment project through external collaboration

Simon Boa, Head of Business Development, Merck Millipore 
*To view the presentation, click here.


16.10 - Patient Capital: The Cancer Research UK Pioneer Fund

Keith Blundy, CEO, Cancer Research Technology
*To view the presentation, click here.

Ian Miscampbell, Managing Partner, Sixth Element Capital LLP

16.30 - Perspectives on early stage investments: the advantages of having a Corporate VC’s input

Hakan Goker, Investment Director, MS Ventures 

16.50 - Chair’s closing remarks

17.00 - Thanks from One Nucleus

Tony Jones, Business Development Director, One Nucleus 

17.10 - Drinks Reception 

18.30 - Close

Gold members: £75 + VAT
Silver member: £175 + VAT
Non-members: £275 + VAT
Academics: £75 + VAT (contact for your code)

Title: Life Science Leadership Series: Cancer Immunotherapies
Start: 2015-02-12 08:30:00Z
End: 2015-02-12 18:30:00Z